Novo Nordisk will present new clinical and real-world data on its obesity treatments, including Wegovy (semaglutide in various doses) and the investigational CagriSema, at the European Congress on Obesity in May 2026. The data highlight sustained weight loss benefits, effects on menopausal symptoms, cardiovascular risk reduction, and patient preferences. This reinforces Novo Nordisk's leadership in obesity treatment with a broad portfolio of GLP-1-based therapies. The presentations will cover both injectable and oral forms, as well as next-generation drug combinations aimed at improving long-term weight management and health outcomes.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
